Skip to main content
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1989 Jun;65(764):417–419. doi: 10.1136/pgmj.65.764.417

Fulminant hyperpyrexia induced by bleomycin.

W H Leung 1, J Y Lau 1, T K Chan 1, C R Kumana 1
PMCID: PMC2429335  PMID: 2481850

Abstract

Mild and self-limiting fever following bleomycin use is common, and a fatal hyperpyrexial response occurs rarely. In previously reported cases, such hyperpyrexia occurred either after the initial administration of the drug or during subsequent therapy following an initial pyrexial response. We describe a fatal hyperpyrexial reaction after bleomycin in a patient with T-cell lymphoma who had had no febrile response when she received her initial injection 3 weeks earlier. Since the occurrence of this hyperpyrexial response is unpredictable, health care workers as well as patients and relatives should always be alert to this potentially lethal complication and prompt measures should be taken in any patient who develops fever after bleomycin use.

Full text

PDF
417

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beutler B., Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med. 1987 Feb 12;316(7):379–385. doi: 10.1056/NEJM198702123160705. [DOI] [PubMed] [Google Scholar]
  2. Blum R. H., Carter S. K., Agre K. A clinical review of bleomycin--a new antineoplastic agent. Cancer. 1973 Apr;31(4):903–914. doi: 10.1002/1097-0142(197304)31:4<903::aid-cncr2820310422>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  3. Britt B. A. Malignant hyperthermia. Clin Anesth. 1975;11(1):61–74. [PubMed] [Google Scholar]
  4. Carter J. J., McLaughlin M. L., Bern M. M. Bleomycin-induced fatal hyperpyrexia. Am J Med. 1983 Mar;74(3):523–525. doi: 10.1016/0002-9343(83)91002-1. [DOI] [PubMed] [Google Scholar]
  5. Crooke S. T., Bradner W. T. Bleomycin, a review. J Med. 1976;7(5):333–428. [PubMed] [Google Scholar]
  6. Dinarello C. A., Ward S. B., Wolff S. M. Pyrogenic properties of bleomycin (NSC-125066). Cancer Chemother Rep. 1973 Nov-Dec;57(4):393–398. [PubMed] [Google Scholar]
  7. Levy R. L., Chiarillo S. Hyperpyrexia, allergic-type response and death occurring with low-dose bleomycin administration. Oncology. 1980;37(5):316–317. doi: 10.1159/000225462. [DOI] [PubMed] [Google Scholar]
  8. Ma D. D., Isbister J. P. Cytotoxic-induced fulminant hyperpyrexia. Cancer. 1980 May 1;45(9):2249–2251. doi: 10.1002/1097-0142(19800501)45:9<2249::aid-cncr2820450905>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  9. Mosher M. B., DeConti R. C., Bertino J. R. Bleomycin therapy in advanced hodgkin's disease and epidermoid cancers. Cancer. 1972 Jul;30(1):56–60. doi: 10.1002/1097-0142(197207)30:1<56::aid-cncr2820300109>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  10. Rosenfelt F., Palmer J., Weinstein I., Rosenbloom B. A fatal hyperpyrexial response to bleomycin following prior therapy: a case report and literature review. Yale J Biol Med. 1982 Sep-Dec;55(5-6):529–531. [PMC free article] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES